

2021 Third Quarter Results

October 29, 2021

 药明康德
WuXi AppTec

Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Non-IFRS Financial Measures

We provide Non-IFRS gross profit and Non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations and goodwill impairment. We also provide adjusted Non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture investments and joint ventures. We further provide EBITDA and adjusted EBITDA. Neither of above is required by, or presented in accordance with IFRS. Meanwhile, to better reflect the operation results and key performance, the Company has adjusted the scope of the foreign exchange-related gains or losses by excluding only the gains or losses that we believe irrelevant to the core business. The comparative financial figures for the comparable periods have been adjusted to reflect the change of the scope.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such Non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted Non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Disclaimer

All intellectual property rights and other rights pertaining to the information and materials presented in the results briefing are owned by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”). Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited. This briefing does not intend to provide a complete statement of the relevant matters. For relevant information, please refer to the 2021 third quarterly report published on the website of Hong Kong Stock Exchange (www.hkexnews.hk).



01 Results Overview

02 Business Highlights

03 Financial Performance

04 Growth Strategy

Notes:

All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or “IFRSs”).
The unit of currency is RMB.

1. Results Overview

Strong Revenue & Profit Growth in 2021 Q3

Revenue

RMB billion

YTD

11.81

+39.8%

16.52

2020 Q1-Q3

2021 Q1-Q3

Q3

4.58

+30.6%

5.98

2020 Q3

2021 Q3

Adjusted Non-IFRS Net Profit

RMB billion

+55.7%

2.44

3.81

2020 Q1-Q3

2021 Q1-Q3

+37.8%

0.99

1.36


2020 Q3

2021 Q3

Consistent Revenue Growth Quarter after Quarter

RMB billion

Consistent revenue growth every quarter except 2020Q1, due to the COVID-19 pandemic



2021 Third-Quarter Business Highlights

“Long-Tail” Strategy

1,300+ New Customers
5,640+ Active Customers

Loyal Customer Base

100% Retention of Our
Top 10 Customers

Small Molecule CRDMO

526 New Molecules
1,548 Molecules;
37 Commercial; **47** Phase III

Cell & Gene Therapies CTDMO

326 Testing
45 Pre-clinical & Phase I
6 Phase II, **10** Phase III

Global Footprint

30 Global Sites & Branch Offices
33,305 Total employees
30,618 Scientists & Technicians



2021 Q1-Q3

16 INDs; **12** CTAs

Cumulatively

136 INDs; **103** CTAs

Clinical Development

1 NDA pending, **1** Phase III
14 Phase II, **73** Phase I

Our Platform & Business Model Continued to Perform Well

Strong, Loyal & Expanding Customer Base


Revenue composition

Existing clients

15,337M, 30%↑

Newly added clients

1,184M



Execute Long-Tail Strategy & Increase Support to Large Pharma


Revenue composition

Top 20 Global Pharma clients

4,699M, 21%↑

All other clients

11,823M, 49%↑




Increase Customer Conversion to Sustain Growth


Revenue composition

Clients using multiple services

14,190M, 40%↑



Strong Revenue Growth from Customers Across All the Regions



2. Business Highlights

WuXi Chemistry Highlights

Financial Performance

- Revenue growth of **47.5%** YoY to **10.08bn**. Our “follow and win the molecule” business model continued to perform.
- Adjusted Non-IFRS gross profit grew by **44.7%** YoY to **4.24bn**.
- Adjusted Non-IFRS gross profit margin is **42.1%**, down by **0.8ppts**.

Drug Discovery

- Revenue of small molecule discovery service grew **42.3%** YoY to **4.44bn**.
- Delivered **~200,000** synthesized compounds to our clients by 3Q21
- Revenue from “long-tail” customers in small molecule discovery service continued to have greater contribution growing **68%**.

CDMO


- Revenue of small molecule CDMO service grew **51.9%** YoY to **5.63bn**.
- Total pipeline of **1,548** molecules, including **37** commercial (**9** new commercial projects YTD-2021), **47** Phase III, **235** Phase II, **1,229** Phase I and pre-clinical projects.
- Oligo & peptide clients and molecules grew **96%** and **97%** respectively versus end-2020.

Capacity Expansion

- On August 3, 2021, STA, a subsidiary of the Company completed the acquisition of a drug product manufacturing facility in **Couvet, Switzerland** from Bristol Myers Squibb and the Company has consolidated its contribution starting from July.
- On Sep 24, 2021, STA closed a **land purchase** in **Delaware, US**, which will be used to build an API and DP manufacturing facilities.


Revenue

RMB billion




Adjusted Non-IFRS Gross Profit

RMB billion




Rich CRDMO pipeline drives sustainable high growth




Strong Growth Providing CDMO Services for New Modalities

Number of Clients for Oligo & Peptide in CDMO



- Expand capacities in oligo & peptide PD and manufacturing
- Strengthen funnel flow from laboratory research to process development and manufacturing
- Keep sourcing new long-tail customers

Number of Molecules for Oligo & Peptide in CDMO



- Form strategic collaboration with industry leaders in oligo & peptide
- Strengthen reliable partnership with key suppliers to ensure sustainable service offerings

WuXi Testing Highlights

Financial Performance

- Revenue growth of **43.9%** YoY to **3.34bn**. Robust growth in lab testing services and strengthened funnel flow from pre-clinical to clinical CRO.
- Adjusted Non-IFRS GP growth **51.4%** YoY to **1.13bn**.
- Adjusted Non-IFRS **GPM** **33.9%**, up by **1.7ppts**.

Lab Testing Services

- Revenue from lab testing services grew **41.9%** YoY to **2.13bn**, revenue excluding medical devices grew **58%** YoY.
- Toxicology services revenue grew **72%** YoY. We are the industry leader for drug safety evaluation services.
- Signed **123** integrated WIND packages

Clinical CRO


- Revenue of clinical CRO and SMO grew **47.4%** YoY to **1.20bn**.
- Provided services to more than **200** projects for our clients, enabling **14** IND approvals and **5** BLA/NDA applications.
- Biometrics business performed well

SMO

- SMO maintained **#1** leadership position in China, with **~4,500** staffs in **153** cities and provide services in **~1,000** hospitals.
- Team expanded **42%** YoY for the first nine months 2021
- Supported **16** products approvals in 2021 Q1-Q3 vs 17 products in all of 2020.


Revenue

RMB billion



Adjusted Non-IFRS Gross Profit

RMB billion



Pre-Clinical Platform: The Largest in Asia Pacific

>> 2021 In Use

110,000

m²,
Lab Space

450

#,
Animal Rooms




>> 2023

165,000

m²,
Lab Space

750

#,
Animal Rooms



WuXi Testing Growth and Synergy Opportunities

Follow the Molecule


through conversion

Win the Molecule

through differentiation

Achieve Synergy

through integration



WuXi Biology Highlights

Financial Performance

- Revenue growth of **33.2%** YoY to **1.42bn**. Robust growth in new modalities and large molecules.
- Adjusted Non-IFRS GP growth **26.6%** YoY to **0.60bn**.
- Adjusted Non-IFRS **GPM 41.8%**, down by **2.2ppts**.

Discovery Biology

- We have the largest discovery biology enabling platform with over **2,000** experienced scientists.
- Established **4 centers of excellence**, for NASH, HBV, Infectious Diseases and Neurobiology.
- Strong growth from both **cancer discovery** service and **rare & Immune disease** Service.

New Modalities


- We continue to build new biology capabilities related to new modalities, including oligo, cancer vaccine, PROTAC, vector platform, drug delivery vehicle.
- Revenue from new modalities and large molecules in WuXi Biology grew **56%**, and its revenue contribution rose to **13.3%** by 3Q21, from 10.4% by end of 2020.

DNA Encoded Library

- We have a leading DNA Encoded Library (DEL) with over **90** billion compounds, **6,000** proprietary scaffolds and **35,000** building blocks.
- Through comprehensive integration of our DEL, protein production and structure-based drug design capabilities, we have established a competitive Target-to-Hit platform to enable our customers.


Revenue

RMB billion



Adjusted Non-IFRS Gross Profit

RMB billion



WuXi Biology in Summary



CAPACITY

- The **largest** discovery biology enabling platforms



CAPABILITY

- Expertise in **all major disease areas** and target classes
- Enable discovery of **all modalities**
- **One-stop** Target-to-Hit solutions



SYNERGY

- **Integrated** support from discovery to PCC
- Collaboration with the **largest** discovery chemistry team in the industry



QUALITY

- Lab and animal facility management based on **global standards**
- State of the art equipment and systems

2,000+ Biologists and scientific managers
¥ 1.42B revenue in 2021 Q1-Q3


- Track record of enabling the delivery of **hits, leads and PCCs** (Preclinical Candidates)
- Track record of enabling the discovery and **approval of innovative medicines** on the market

>83% revenue in 2021 comes from customers using both WuXi Biology and Chemistry platforms

Entrusted by **20** of global top 20 pharmaceutical companies and **>1,100** collaborators

A Global Leader in DNA Encoded Library (DEL)

WuXi DNA Encoded Libraries



- **Largest** global customer base
- **Pioneer DEL Kit** business model



- **Unique** WuXi library with drug like scaffolds
- 32 applied patents of invention, 8 authorized
- 12 published academic papers
- **World renowned** academic advisors



- **Strong synergy** with WuXi Chemistry capabilities



DELopen

>90B
compounds

>200
libraries

6,000
proprietary
scaffolds

35,000
building blocks

WuXi ATU Highlights

Financial Performance

- Revenue declined **5.2%** to **0.74bn**. Decline largely due to the pandemic impacting the region and BLA filing delay by cell therapy clients. ATU China grew 187%, partly offset the decline in US.
- Adjusted Non-IFRS gross profit decline **89.7%** to **0.01bn**.
- Adjusted Non-IFRS GPM **1.9%**.

Projects

- We focused on improving our CTDMO integrated enabling platform and provided testing services to **326** projects, and provided development and manufacturing services for **45** pre-clinical and Phase I projects, **6** Phase II projects, **10** Phase III projects.


Capabilities

- Backlog and revenue show sign of recovery in the U.S..
- Increased **manufacturing efficiency and utilization rate**, to ensure the timely delivery.
- **Enhanced technical process of plasmid, LVV and AAV**, further lowering the viral-vector cost of manufacturing and increasing our competitiveness.


Capacities

- **Shanghai Lin-gang site** opened in Oct 2021. It is the fourth site for WuXi ATU globally, providing testing, process development and manufacturing services to global clients.

Revenue




Adjusted Non-IFRS Gross Profit



Growing Pipeline on the fully Integrated CTDMO Platform

Testing and Manufacturing Funnel



Provided Global Integrated CTDMO Services to **Cell & Gene Therapy** product development

4 projects are in BLA preparation stage

61
MFG
Projects

WuXi DDSU Highlights

Financial Performance

- Revenue growth of **16.4%** YoY to **0.93bn**.
- Adjusted Non-IFRS GP growth **-0.6%** YoY to **0.41bn**.
- Adjusted Non-IFRS GPM **44.2%**.

Success-based Services

- During the Reporting Period, our success-based drug discovery service unit filed INDs for **16** drug candidates and obtained **12** CTAs.
- Cumulatively submitted **136** new chemical entity IND filings and obtained **103** CTAs, with **1** project in NDA review stage, **1** project in Phase III clinical trial, **14** projects in Phase II clinical trials, and **73** projects in Phase I clinical trials.


Innovative R&D

- Among the 136 projects that INDs were filed or currently in clinical stage, over **70%** of the projects rank **top 3** in China, in terms of their drug development progress among same-class drug candidates.

Sales Royalties


- On July 24, our partner submitted the **first NDA filing** for the drug discovered by our DDSU
- Upon the products' successful launch to the market by our customers, we would begin receiving **sales royalty income**.

Revenue
RMB billion



Adjusted Non-IFRS Gross Profit


RMB billion



Success-based Business Model with Potential Upside

136 IND filings

70%+ Top 3 in China¹




Note:

1. Rank by clinical development speed among same-class drug candidates


3. Financial performance

Financial Performance


Revenue




Adjusted Non-IFRS Gross Profit



Net Profit Attributable to Owners of the Company




Adjusted Non-IFRS Net Profit Attributable to Owners of the Company



Segment Revenue


WuXi Chemistry

RMB MM




WuXi Testing

RMB MM




WuXi Biology

RMB MM




WuXi ATU

RMB MM




WuXi DDSU

RMB MM




Segment Adjusted Non-IFRS Gross Profit


WuXi Chemistry RMB MM




WuXi Testing RMB MM




WuXi Biology RMB MM



WuXi ATU RMB MM



WuXi DDSU RMB MM




IFRS & Adjusted Non-IFRS Measures

RMB Million	2021'Q3	2020'Q3	YoY	2021'Q1-Q3	2020'Q1-Q3	YoY
Revenue	5,985	4,583	30.6%	16,521	11,815	39.8%
<i>IFRS Gross Margin%</i>	36.8%	38.5%		36.8%	37.4%	
Adjusted Non-IFRS Gross Margin%	38.3%	40.6%		38.7%	39.8%	
IFRS Operating Profit	1,330	894	48.8%	4,384	2,957	48.3%
<i>IFRS Operating Profit Margin%</i>	22.2%	19.5%		26.5%	25.0%	
Adjusted Non-IFRS Operating Profit	1,639	1,223	34.0%	4,626	3,053	51.5%
Adjusted Non-IFRS Operating Profit Margin%	27.4%	26.7%		28.0%	25.8%	
Net Profit Attributable to Owners of the Company	887	651	36.2%	3,562	2,368	50.4%
Adjusted Non-IFRS Net Profit Attributable to Owners of the Company	1,358	986	37.8%	3,806	2,445	55.7%
IFRS EPS (RMB)						
-Basic	0.30	0.23	30.4%	1.22	0.86	41.9%
-Diluted	0.30	0.23	30.4%	1.21	0.85	42.4%
Adjusted Non-IFRS EPS(RMB)						
-Basic	0.46	0.34	35.3%	1.31	0.89	47.2%
-Diluted	0.46	0.33	39.4%	1.30	0.87	49.4%
Weighted Average Number of Shares'000	2,929,033	2,797,834		2,911,521	2,759,332	
Fully Diluted Weighted Average Number of Shares'000	2,949,276	2,821,246		2,931,763	2,782,745	

Note: "IFRS Operating Profit" is calculated based on IFRS Gross Profit deducted by SG&A, R&D expenses and Impairment losses while adding Other income and Other gains and losses, which aligns with the disclosure in Group Consolidated Profit & Loss Statement.

Adjusted Non-IFRS Net Profit


RMB Million	2021' Q3	2020' Q3	2021'Q1-Q3	2020'Q1-Q3
Net Profit Attributable to the owners of the Company	887	651	3,562	2,368
Add:				
Share-based compensation expenses	108	138	419	413
Convertible Bonds issuance expenses	1	1	2	4
Fair value (gains)/losses from derivative component of Convertible Bonds	-24	190	1,469	676
Foreign exchange related losses	7	161	73	121
Amortization of acquired intangible assets from merge and acquisition	15	9	41	26
Non-IFRS Net Profit Attributable the owners of the Company	993	1,150	5,567	3,609
Add:				
Realized and unrealized losses/(gains) from venture investments	368	-166	-1,780	-1,179
Realized and unrealized share of (gains)/losses from joint ventures	-3	2	19	15
Adjusted non-IFRS net profit attributable to the owners of the Company	1,358	986	3,806	2,445



Capital Expenditure and Total Debt

Capital Expenditure¹


RMB MM



Total Borrowings²

RMB MM

Long-term
Short-term



Note:

- 1. Capital expenditure includes purchase of property, plant and equipment, other intangible assets, prepaid lease payments and other long-term expenses.
- 2. Total borrowings include short-term and long-term borrowings, excluding the lease liabilities and convertible bond issued in Q3'2019.

4. Growth Strategy

We Continue to Believe



- 1 Our integrated **CRDMO** and **CTDMO** model is one-of-a-kind engine in global pharmaceutical and biotech industry
- 2 Our integrated **5 platforms** with **comprehensive capabilities and capacities** will propel our company to achieve strong growth for many years to come
- 3 Our proven strategy of enabling entrepreneur and biotech clients to lower entry barriers of drug discovery and development and the “**Follow the Molecule**” execution strategy position us well in the global healthcare ecosystem
- 4 Our **experienced** management team and talented 33,000+ employees worldwide are the most important assets to deliver shareholder values
- 5 Our **track record and reputation** of consistently delivering excellent results to our clients and shareholders won the trust for sustainable growth of our company